AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 2022
Unique, intra-articular administration of AMB-05X yielded sustained, high synovial concentrations with low systemic exposures and positive clinical efficacyREDWOOD CITY, Calif.,...